VANCOUVER, Nov. 26 /CNW/ - Biotech Holdings (the "Company", OTC BB:
BIOHF.OB) reports that it has signed an agreement (the "Agreement") with a
private company (the "UAE Distributor"), pursuant to which, for a period of
three years with an option to renew, the UAE Distributor will have an
exclusive right to market and distribute Sucanon Type II Diabetes drug
("Sucanon") in the United Arab Emirates including Dubai.
Pursuant to the agreement, the UAE distributor will have the option of
receiving Sucanon either in pre-mix form from Canada or in tableted form from
the Company's contract tableter in Mexico.
The United Arab Emirates according to information quoted in the Globe and
Mail newspaper November 14, 2007, page L6 and attributed to Diabetes Forecast
magazine, published by the American Diabetes Association, has the world's
second highest percentage of adults afflicted by Type II Diabetes, at 19.5 %,
approximately one in five adults.
This release has been approved by the Board of Directors of Biotech
Robert B. Rieveley, President
On behalf of the Board of Directors
Phone: 604 295 1119
Any statements made in this release that are not based on historical fact
are forward-looking statements. Any forward-looking statements made in this
release represent management's best judgement as to what may occur in the
future. However, actual outcome and results are not guaranteed and are subject
to certain risks, uncertainties and assumptions and may differ materially from
what is expressed. There is no assurance that sales, once begun in any
specific market, will be material.
For further information:
For further information: Austin Rand at Biotech Holdings,
1-888-216-1111, or firstname.lastname@example.org. For background information on Biotech
Holdings, or to receive news updates, see www.biotechltd.com